Join
Live feed
·
PRReleasevia Quantisnow
BioVie Inc. logo

BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

ByQuantisnow·Wall Street's wire, on your screen.
BIVI· BioVie Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIVI (BioVie Inc.) and more on Quantisnow.